Appendix: Claims as pending upon entry of this amendment

1. (twice amended) A method of inhibiting or reducing stenosis or restenosis of a blood vessel following injury to vascular tissue in a region of the blood vessel of a patient in need of treatment thereof, comprising:

administering systemically or at the site of the injury a pharmaceutically acceptable composition comprising a compound which specifically inhibits or reduces leukocyte [CD11d/CD18] integrin -mediated adhesion or function, wherein the integrin is selected from the group consisting of Mac-1 (CD11b/CD18), LFA-1 (CD11a/CD18), p150,95 (CD11c/CD18), and CD11d/CD18, wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with [CD11d/CD18] the integrins or their ligands and which block the interaction of the [CD11d/CD18] the integrins or their ligands with vascular cells; molecules which inhibit expression of the [CD11dCD18] integrins or their ligands, and peptides and peptidomimetics derived from the [CD11d/CD18] integrins or their ligands which block the interaction of the [CD11d/CD18] integrins or their ligands with vascular cells or tissues, in an amount effective to inhibit or reduce stenosis or dependent restenosis of a blood vessel following injury to vascular tissue.

2. The method of claim 1 wherein the leukocytes are monocytes or granulocytes.

3. The method of claim 1 wherein the injury arises from angioplasty, atherectomy, endovascular stenting, coronary artery bypass surgery, peripheral bypass surgery, or transplantation of cells, tissue or organs.

4. The method of claim 1 wherein the composition is in a form selected from the group consisting of solutions, gels, foams, suspensions, polymeric carriers, and liposomes.

5. (twice amended) The method of claim 1 wherein the [CD11d/CD18] integrin is selected from the group consisting of [Mac-1,] LFA-1 (CD11a/CD18), [and] p150,95 (CD11c/CD18), and CD11d/CD18.

6. (twice amended) The method of claim 5 wherein the [CD11d/CD18] integrin is Mac-1 (CD11b/CD18).

7. The method of claim 6 wherein the ligand is selected from the group consisting of ICAM-1, fibrin(ogen), C3bi, and factor X.

8. (twice amended) The method of claim 1 wherein the compound is selected from the group consisting of antibodies and antibody fragments that are immunoreactive with [CD11d/CD18] the integrins or their ligands and which block the interaction of the [CD11d/CD18] integrins or their ligands with vascular cells[; molecules which inhibit expression of the CD11d/CD18 integrins or their ligands, and peptides and peptidomimetics derived from the CD11d/CD18 integrins or their ligands which block the interaction of the CD11d/CD18 integrins or their ligands with vascular cells or tissues].

9. (twice amended) The method of claim 5 wherein the [CD11d/CD18] integrin is LFA-1 and the ligand is selected from the group consisting of ICAM-1, ICAM-2, ICAM-3.

10. (amended) The method of claim 6 wherein the compound is an antibody or antibody fragment immunoreactive with Mac-1 (CD11b/CD18).

11. The method of claim 1 wherein the compound is administered to a patient in need thereof prior to vascular intervention.

12. The method of claim 11 wherein the compound is administered to a the patient prior to and after vascular intervention, until healing has occurred.